Background: Circulating tumor cells (CTCs) are biomarkers for non-invasively 26 measuring the evolution of tumor genotypes during treatment and disease progression. 27 Recent technical progress has made it possible to detect and characterize CTCs at the 28 single-cell level in blood. 29 Content: Most current methods are based on epithelial cell adhesion molecule 30 (EpCAM) detection, but numerous studies have demonstrated that EpCAM is not a 31 universal marker for CTC detection since it fails to detect both carcinoma cells that 32 undergo epithelial-mesenchymal transition (EMT), and CTCs of mesenchymal origin. 33 Moreover, EpCAM expression has been found in patients with benign diseases. A large 34 proportion of the current studies and reviews about CTCs describe EpCAM based 35 methods, but there are evidences that not all tumor cells can be detected using this 36 marker. Here we describe the most recent EpCAM-independent methods for enriching, 37 isolating and characterizing CTCs, based on physical and biological characteristics, and 38 point out their main advantages and disadvantages. 39 Summary: CTCs offer an opportunity to obtain key biological information required for 40 the development of personalized medicine. However there is no universal marker of 41 these cells. To strengthen the clinical utility of CTCs, it is important to improve existing 42 technologies and develop new, non-EpCAM based systems to enrich and isolate CTCs.
cells [20] . These cytological alterations result in the differences of their mechanical 124 properties, providing CTCs with several capabilities. The cytoskeletal stiffness of CTCs 125 is dynamically modified. This flexibility may facilitate their invasion to distal sites from 126 the primary tumor, and may confer their resistance to damage from fluid shear stress 127 within the blood vessels during the metastatic process [21] . These modifications in the 128 stiffness alter the conservation of the membrane structure, which in turn affects their 129 surface charge and electrical properties [21] . Various approaches have been used to 130 exploit the differences in physical properties between tumor cells and blood cells as a 131 means of enriching and separating CTCs from blood samples (Figure 1 ).
133
Density gradient centrifugation is a conventional approach for separating blood 134 components based on differences in their sedimentation coefficients. As whole blood is 135 deposited in the liquid gradient and subjected to centrifugation, cells will distribute 136 along the gradient depending on their density (Figure 1 , Table 1 ). Erythrocytes or 137 polymorphonuclear leukocytes migrate to the bottom, while mononuclear leukocytes 138 and CTCs remain at the top as a buffy coat [22] . Percoll, Ficoll-Hypaque® (GE 139 Healthcare Life Sciences, Little Chalfont, United Kingdom) and OncoQuick® (Greiner 140 Bio-One, Kremmünster, Austria) are the most commonly used density gradient media in 141 pre-clinical and clinical research. Ficoll-HyPaque®, formed by the copolymerization of 142 sucrose and epichlorohydrin, is mainly used in biology laboratories to recover 143 peripheral blood mononuclear cells. Despite its long history of use in laboratories, there 144 are some pitfalls associated to this technique, such as the possible loss of tumor cells 145 that migrate either to the plasma fraction or to the bottom of the gradient due to the 146 formation of aggregates [22] . It has been suggested that this cell loss may be due to the 147 cytotoxicity of the density medium [23] . Alternative to Ficoll, there is Percoll density 148 (GE Healthcare Life Sciences) gradient medium made of a colloidal silica particle 149 suspension. The main advantages over Ficoll include reduced toxicity and a wider 150 density gradient range [23] . There are certain discrepancies in the literature regarding 151 the use of Percoll since some studies report a high purity rate [24] 
173
Membrane microfilters are composed of a semipermeable membrane with a 2D 174 array of micropores. A membrane with a pore size diameter of 8µm has been 175 demonstrated to be optimal for CTC retention [30] . The typical configuration used for 176 microfiltration is dead-end filtration (Figure 2A) , in which the blood flow is 177 perpendicular to the membrane. The main limitation of this strategy is that the layer of 178 cells retained on the membrane can reduce the efficiency of recovery due to the build-up 179 of filtration resistance [32] ( Table 1) . To overcome this issue, Zheng et al. created a 3D 180 membrane microfilter consisting of two pored layers ( Figure 2B ), between which CTCs 181 are retained [32] . In contrast to conventional microfiltration devices, this system reduces 182 the tension stress on the cell plasma membrane and demonstrates a high recovery rate 183 (86% with a theoretically fast throughput of 3.75 mL/min) [32].
184
Another system based on a 2D membrane slot filter ( Figure 2C to the next step, due to particle deformability and can limit the use if this device [41] .
247
Carefully applied microfluidic approaches are capable of achieving both 248 excellent purity of more than 80% and high recovery rates with little disturbance to the 249 CTCs. However, these advantages come at the expense of lower throughput requiring 250 either reduced sample volumes or prolonged periods of time to process samples (e.g., 251 several hours to process a full tube of blood). fractionation was the ApoStream™ system (ApoCell Inc., Houston, TX) ( Figure 4A ).
270
To use this methodology, an initial enrichment step is required. Recovery rate is over 271 70% and the viability more than 97%; however, the purity obtained is less than 1%, EpCAM as it is expressed in all epithelial cells but is absent from blood cells [13, 50] . Table 1 ).
301
Immunoaffinity-based CTC isolation is based on antibody-conjugated magnetic 302 nanoparticles or microbeads that often bind to a specific surface antigen [51, 52] . After 303 antigen-antibody interaction, the sample is exposed to a non-uniform magnetic field to 304 capture labeled cells. This method can attain high recovery and purity rates, with single-305 step detection and isolation of CTCs [51, 53] . The performance of the immunomagnetic 306 method depends directly on both the expression and specificity of the target antigen, as 307 well as on the binding quality of the associated antibody, the efficiency of the 308 immunomagnetic labeling process and magnetic particles, and the separation 309 mechanism designed to isolate labeled cells. A "cocktail" of antibodies targeting 310 multiple antigens can also be used to partially overcome the lack of specificity of 311 current tumor markers [51, 54] . Another approach is negative isolation of CTCs by first 312 lysing erythrocytes and using specific markers to magnetically deplete leukocytes.
313
CD45 is the most frequently used marker for leukocyte depletion. The RosetteSep ® 314 (STEMCELL Tech, Cambridge, United Kingdom), is a CTC negative selection system 315 based on a mixture of antibodies that specifically crosslink red blood cells to each other 316 and to white blood cells, forming cell rosettes consisting of multiple red and white 317 blood cells. Due to the higher density of these clusters, they can effectively be separated 318 from CTCs by a single centrifugation step. Negative selection methods are completely 319 independent with regard to CTC phenotype, so they are not biased by a particular CTC 320 marker. Negative selection also leaves CTCs untouched, which may result in higher 321 viability. To achieve an acceptable degree of CTC purity, this separation method 322 requires a very high specificity to remove all the leukocytes and needs to avoid non-323 specific CTC binding. The binding between primary antibody and magnetic particles 324 can be a direct (single-step) or indirect (two-step) method. The latter is composed of 325 secondary antibodies that are already bound to magnetic particles and can specifically 326 bind to an epitope on the primary antibody, potentially reaching higher labeling 327 efficiency. This indirect approach shows a 15-fold increase in labeling efficiency 328 compared to direct methods [55] . 329 Regarding the use of the magnetic separation procedure to recover labeled cells, 330 there are many different alternatives. In the batch separation approach, the whole 331 labeled sample is subjected to a magnetic field at once, resulting in the migration of Concluding remarks 380 We have highlighted the non-EpCAM-based methods for CTC enrichment/isolation.
381
The major advantage of these techniques is that they can enrich for CTCs that do not 382 have EpCAM expression. However, many challenges associated with current 383 methodologies must be faced, such as the need to improve purity and recovery rates, 384 throughput, cell viability after recovery, and enrichment rates.
385
It would be beneficial to identify properties exclusive to CTCs, which may take 386 the form of a single "master" marker or a combination of antibodies able to recognize 387 all the CTCs present in the sample. Moreover, it would be desirable that those 388 properties or markers were able to distinguish between metastatic and non-metastatic 389 CTCs. Unfortunately, current knowledge does not make it possible to clearly identify 390 and classify CTCs. This information is of most importance in clinics, for the prognosis 391 of the disease, treatment decisions or the effectiveness of the treatment applied.
392
Despite the numerous methods for isolating CTCs described in the literature, based on the depletion of normal CD45 + hematopoietic cells to limit loss of CTCs with 421 high phenotypic plasticity. However, it should be noted that not all CD45cells in the 422 blood are tumor cells (e.g., circulating endothelial cells) [11] . 423 In the last decade, the strong interest of CTCs has accelerated the development 424 of numerous isolation technologies based on EpCAM independent methods.
425
Technologies based on physical approaches (density gradient centrifugation, 426 microfiltration, mircofluidics, dielectrophoresis) or biological properties of CTCs (e.g. 427 membranous markers) have been demonstrated. However, further improvements in pre-428 enrichment steps will improve the capture and characterization of these cells. bead sizes were used to implement a blood/plasma separator at the inlet of the 711 microchannel. When whole blood was dropped into the inlet of the microchannel, the 712 structure allowed for the capillary flow of blood through the hetero-packed beads.
713
During this movement of blood, the red blood cells pass through small pores while large 714 cells such as CTCs are blocked from flowing into the channel. 
